Fernando Escalante Barrigón-rekin lankidetzan egindako argitalpenak (12)

2024

  1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2023

  1. Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

    Haematologica, Vol. 108, Núm. 10, pp. 2753-2763

2022

  1. Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival

    British Journal of Haematology, Vol. 198, Núm. 2, pp. 278-287

2021

  1. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852

  2. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial

    Blood Cancer Journal, Vol. 11, Núm. 5

2017

  1. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma

    Haematologica, Vol. 102, Núm. 5, pp. 922-931

2016

  1. Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma

    Leukemia, Vol. 30, Núm. 10, pp. 2026-2031

2015

  1. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

    Leukemia

  2. The cellular origin and malignant transformation of Waldenström macroglobulinemia

    Blood, Vol. 125, Núm. 15, pp. 2370-2380

2014

  1. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: New criteria for risk of progression to myeloma

    Blood, Vol. 124, Núm. 8, pp. 1300-1303

  2. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: New criteria for differential diagnosis and risk stratification

    Leukemia, Vol. 28, Núm. 1, pp. 166-173

2013

  1. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728